Pembrolizumab Plus mRNA Vaccine Leads to Improved RFS in High-Risk Melanoma
Source: Targeted Oncology, June 2023
In the adjuvant setting for high-risk melanoma, findings from the phase 2b mRNA-4157-P201/KEYNOTE-942 trial (NCT03897881) that evaluated mRNA-4157/V940 in combination with pembrolizumab (Keytruda) showed improved recurrence-free survival (RFS) compared with pembrolizumab alone.
The findings, which were presented during the American Association for Cancer Research Annual Meeting 2023, showed that the overall 18-month RFS rate was 78.6% (95% CI, 69.0%-85.6%) with the combination vs 62.2% (95% CI, 46.9%-74.3%) with pembrolizumab alone, leading to a 44% reduction in the risk of disease recurrence or death (HR, 0.561; 95% CI, 0.309-1.017; 1-sided P?=?.0266).
These data, which were presented by senior author Jeffrey S. Weber, MD, PhD, were found to be statistically significant and clinically meaningful.